Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary

by Anna Nicholson, Rebecca A. English, Rita S. Guenther et al.
Board on Health Sciences Policy; Institute of Medicine, 2013

170 pp. 1.7 MB:

To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available.

(Visited 48 times, 1 visits today)
This entry was posted in Essential Medicines, General, Tuberculosis. Bookmark the permalink.